Loading
Monoclonal and Polyclonal Antibodies Research / Cancer Research and Treatments · Journal article
Journal of the American Chemical Society · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a proof-of-concept study presenting engineered nonpathogenic E. coli K12 designed to deliver surface-anchored CD24-targeting protein degradation chimeras and PD-L1-blocking nanobodies to tumors in mice. In subcutaneous breast and orthotopic hepatocellular carcinoma models, the engineered bacteria achieved tumor growth inhibition and prolonged survival through synergistic macrophage activation and CD8+ T cell immunity; however, this is early preclinical work without comparator arms, human relevance data, or toxicology characterization.
Preclinical in vivo efficacy study in syngeneic tumor models. Immunocompetent mice bearing subcutaneous breast cancer and orthotopic hepatocellular carcinoma. Intervention: Engineered nonpathogenic E. coli K12 expressing surface-anchored transferrin-CD24 antibody chimeras and constitutively secreted PD-L1-blocking nanobodies.
Engineered E. coli K12 achieved tumor-targeted CD24 degradation in both subcutaneous breast and orthotopic hepatocellular carcinoma models In vivo administration led to marked tumor growth inhibition and prolonged animal survival Mechanism involved remodeling of tumor microenvironment through M1-like macrophages and tumor-resident memory (TRM)-like CD8+ T cells
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
First-in-kind proof-of-concept study in animal models demonstrating a novel engineered bacterial platform; lacks human efficacy data, comparator arm, and dose-ranging or safety characterization needed to establish clinical relevance.
As stated by the source record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Microbial cell therapies hold considerable promise as programmable and versatile modalities for targeted interventions in complex biological environments. Here, we developed a living bacterial delivery platform that could leverage its endogenous metabolism to synchronize the release of surface-anchored targeted protein degradation (TPD) chimeras and the secretion of immune-modulatory nanobodies (Nbs) for enhanced antitumor efficacy. By means of metabolic labeling coupled with bioorthogonal click chemistry, transferrin (Tf)-CD24 antibody chimeras (TransCACs) were covalently displayed on the surface of nonpathogenic Escherichia coli (E. coli) K12. In parallel, this strain was equipped with a constitutive expression module for the in situ biosynthesis of PD-L1-blocking nanobodies. Capitalizing on the natural tumor tropism of bacteria, our engineered E. coli K12 achieved tumor-targeted CD24 degradation, thereby augmenting macrophage-mediated phagocytosis and synergizing with PD-L1 blockade to elicit robust tumor-specific CD8+ T cell immunity. In vivo administration of engineered microbes led to marked tumor growth inhibition in both subcutaneous breast and orthotopic hepatocellular carcinoma models, along with prolonged animal survival, driven by remodeling of the suppressive tumor microenvironment through coordinated crosstalk between M1-like macrophages and tumor-resident memory (TRM)-like CD8+ T cells. Altogether, this integrated genetic engineering and metabolic labeling of bacteria (InGeM) opens avenues for the development of next-generation microbe-based cancer immunotherapies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.